A new nutritional supplement has been approved by the US Food and Drug Administration for children who are vulnerable to epilepsy, a condition in which a person’s seizures stop for short periods of time.
The Food and Drugs Administration approved the product, called Natalum, as a dietary supplement for children, adults, and people with other disorders who may be affected by the condition.
The supplement was developed by scientists at the University of Utah and the University at Buffalo, who hope the drug will also be able to help improve brain health.
Natalum is made by the University for Children’s Hospital and was developed as a non-steroidal anti-inflammatory drug, which can be taken orally or inject.
Norton is one of the largest pharmaceutical companies in the world.
It was founded by the late Paul Scherr, the co-founder of the pharmaceutical company Eli Lilly and the father of Eli Lilly’s global brand.
Scherr died in 2008, but his son, Paul Scherra, took over the company after his father’s death.
He said the company was created because of concerns that a lack of effective treatment options for pediatric epilepsy was creating a growing number of children with severe and chronic seizures.
Sherryra said Natalam was the result of his efforts to find a solution to the issue and that it is currently the only dietary supplement approved by regulators in the United States for children.
Sherra said he is also working with researchers at the Mayo Clinic and the Johns Hopkins University to develop additional medications for children with epilepsy.
Navalin, which was approved in April as an anti-convulsant by the FDA, has also been approved for use by children with developmental disorders.
It is a form of a medication that can help relieve tremors associated with autism spectrum disorders.
Neralum can be used for people who are prone to seizures and who are at risk of developing epilepsy.
Natalas primary ingredient is an amino acid called arginine.
Steroids and antibiotics can also be used in the treatment of seizures, and Natalums treatment includes taking a vitamin and mineral supplement that is designed to improve brain functioning.
In the United Kingdom, a company called GlaxoSmithKline is also looking to develop Natalumes treatment for children in need of treatment.
The drug is currently being studied by the British Drug Development Authority and has been given preliminary approval by the country’s National Institute for Health Research.
Stern is an associate professor of medicine at the Perelman School of Medicine at the Johns Wayne University School of Pharmacy and Health Science.